Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Slides:

Advertisements

Similar presentations

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Advertisements

Herceptin + 17-AAG Combination BT-474 Tumors

Ki67 SPATIAL DISTRIBUTION Ki67 PROLIFERATION REOXYGENATION 48 hours SUPPLEMENTARY FIGURES S1ABC Figure S1. Reoxygenation and Repopulation at 48 hours in.

Complete the following metric conversions using the correct number of significant figures a cm to m b m to km c cm to mm d

Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification Tumor cells were continuously treated with increasing.

Supplemental Data. Supplemental Data contains three figures. Supplemental data Figure 1 shows an example of the HPLC technique used to measure BH4:BH2.

CohortTreatment groups DoseMode of administration Number of animals DT01 + OXA + 5-FU sacrificed day 22 Vehicle (NaCl + glucose) 0.9% 5% IP 9 OXA 5-FU.

The reading is 7.38 mm. The reading is 7.72 mm.

Supplementary information Figure S1 Parental Mock ANXA1-V5 GAPDH MCF7-EV MCF7-V5 4 5 ANXA1 ANXA1-V5 Tubulin MCF7-parental MCF7-EV MCF7-V A B C ANXA1.

Convert into scientific notation:

Fig. 1. Effects of letrozole (Let; 10 μg/day) and tamoxifen (Tam; 100 μg/day) and their combined or alternating treatment on the growth of MCF-7Ca breast.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Drug concentration (μM)

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Median Tumor Development Time

Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells

Supplementary Figure S13

Supplementary Figure 2 Secondary transplanted brain tumors from PASC1 express human GH. Immuno-fluorescence staining of brain sections from mice implanted.

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

[68Ga]Pentixafor PET imaging of MM xenografts Real‐time PCR analysis of cxcr4 transcript expression levels in HeLa (negative control) and in MM cell lines.

Volume 19, Issue 1, Pages (January 2017)

Toll-Like Receptor 5 Engagement Modulates Tumor Development and Growth in a Mouse Xenograft Model of Human Colon Cancer Sang Hoon Rhee, Eunok Im, Charalabos.

Effects of SC144 on in vivo ovarian tumor.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Figure 2S (Supplementary Data)

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Thalidomide Enhances the Anti-Tumor Activity of Standard Chemotherapy in a Human Melanoma Xenotransplatation Model Elisabeth Heere-Ress, Johannes Boehm,

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Volume 15, Issue 3, Pages (March 2009)

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

Effect of PV1(RIPO) on s.c.

Supplementary Figure 5: Effect of S48168 on normalized organ and skeletal muscle weights after 12 weeks of treatment for all the experimental groups from.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis Russell F. Jacoby, Carolyn E.

Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice Christiane Thallinger, Johannes.

TFAP2A knockdown inhibits tumor growth in vivo.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

Active AR signaling in enzalutamide-resistant xenograft tumors.

In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Effect of CDV on human SF7796 xenografts in vivo.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

PDL192 and inhibit the growth of xenograft tumors.

FGFR2 amplification in primary human gastric tumors predicts for response to NVP-BGJ398. FGFR2 amplification in primary human gastric tumors predicts for.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Presentation transcript:

Supplementary Figures&Legends

Figure1. Subcutaneous xenograft tumor models of the control group.

Figure1. One of the subcutaneous xenograft tumor models in the control group.As shown in the picture, the width of the tumor is 10mm, and the tumor volume is about 1300mm 3, which is the mean volume of tumors in control group.

Figure3. Subcutaneous xenograft tumor models treated with 10mg S(MeO)TLC. The tumor volume of mice in this group is varies, but the mean volume is lower than the control group significantly(P ＜ 0.05).

Figure4. Subcutaneous xenograft tumor models treated with 20mg S(MeO)TLC. The average tumor volume of mice in this group is significantly lower than the control group and the 10mg group(P ＜ 0.05). In addition, it is noted that there was necrosis on the tumor surfaces of some treated mice, especially in the 20 mg kg–1 S(MeO)TLC treatment group.